Use of SU11248 to inhibit proangiogenic growth factors in renal cell carcinoma patients
نویسندگان
چکیده
منابع مشابه
Prognostic value of p53 in renal cell carcinoma
Background and Objectives: RCC is one of the most common genitourinary cancers. Accurate prediction of prognosis would be valuable for adjuvant trial design, counseling and effectively scheduling follow up visits. P53 is a tumor suppressor gene that expresses a protein that involved in both cell-cycle ar...
متن کاملPrognostic factors in patients with advanced renal cell carcinoma.
BACKGROUND The purpose of this study was to evaluate prognostic factors in patients with RCC. MATERIALS AND METHODS The expression of several biomarkers were measured by immunohistochemistry (IHC), together with 2 analytic factors (thrombocytosis and neutrophilia), in 135 patients with advanced RCC treated with new targeted drugs (NTDs) (n = 67) and/or cytokines (CKs) (n = 68)-with 23 of the ...
متن کاملThe Prognostic Factors for Patients with pT1a Renal Cell Carcinoma
PURPOSE Although the prognosis of patients with pT1a stage renal cell carcinoma (RCC) is generally good, some of these patients show distant metastasis. In this study, we intended to identify the perioperative and pathologic prognostic factors for patients with pT1a stage RCC. MATERIALS AND METHODS A total of 93 patients who were diagnosed with pT1aN0M0 RCC between January 1995 and December 2...
متن کاملPrognostic factors in renal cell carcinoma
We studied 569 cases of renal cell carcinoma in the file5 of the Department of Pathology of the Nor~vegian Radium Hospital from 1964 to 1974. A nephrectorny had been perfornied in all cases. Clinical information on sex, age, survival time and metastases was traced. The histological slides were examined and turnour growth pattern, cell type, cell shape, nuclear atypia, abnormal nucleoli, nuclear...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nature Clinical Practice Urology
سال: 2006
ISSN: 1743-4270,1743-4289
DOI: 10.1038/ncponc0416